283 related articles for article (PubMed ID: 18940681)
21. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
Ferrara F; Palmieri S; Pedata M; Viola A; Izzo T; Criscuolo C; Mele G
Hematol Oncol; 2009 Mar; 27(1):40-5. PubMed ID: 19206083
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation for acute myeloid leukemia.
Linker CA
Bone Marrow Transplant; 2003 May; 31(9):731-8. PubMed ID: 12732879
[TBL] [Abstract][Full Text] [Related]
24. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Schlenk RF; Benner A; Krauter J; Büchner T; Sauerland C; Ehninger G; Schaich M; Mohr B; Niederwieser D; Krahl R; Pasold R; Döhner K; Ganser A; Döhner H; Heil G
J Clin Oncol; 2004 Sep; 22(18):3741-50. PubMed ID: 15289486
[TBL] [Abstract][Full Text] [Related]
25. Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia.
Ferrara F; Viola A; Copia C; Falco C; D'Elia R; Tambaro FP; Correale P; D'Amico MR; Vicari L; Palmieri S
Hematol Oncol; 2007 Jun; 25(2):84-9. PubMed ID: 17361983
[TBL] [Abstract][Full Text] [Related]
26. Autologous stem cell transplantation for patients with chronic myeloid leukemia. The Argentine Group of Bone Marrow Transplantation (GATMO) experience.
Koziner B; Dengra C; Lucero G; Klein G; Cánepa C; Milovic V; Milone G; Robinson A; Cerutti I; Saporito G; Kusminsky G; Milone J; Bordone J; Lastiri F;
Cancer; 2002 Dec; 95(11):2339-45. PubMed ID: 12436440
[TBL] [Abstract][Full Text] [Related]
27. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
[TBL] [Abstract][Full Text] [Related]
28. New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients.
Bruserud O; Tjønnfjord G; Gjertsen BT; Foss B; Ernst P
Stem Cells; 2000; 18(5):343-51. PubMed ID: 11007918
[TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients.
Isidori A; Bonifazi F; Visani G; Gherlinzoni F; Baccarani M; Lemoli RM
Haematologica; 2005 Jan; 90(1):139-41. PubMed ID: 15642686
[TBL] [Abstract][Full Text] [Related]
30. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
31. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
Zhou A; Shi Y; Feng F; Lu S; He X; Han X
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemia and the position of autologous stem cell transplantation.
Breems DA; Löwenberg B
Semin Hematol; 2007 Oct; 44(4):259-66. PubMed ID: 17961725
[TBL] [Abstract][Full Text] [Related]
33. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
35. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
Jung AS; Holman PR; Castro JE; Carrier EK; Bashey A; Lane TA; Nelson CL; Pu M; Messer K; Corringham SM; Ball ED
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1306-13. PubMed ID: 19747639
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.
Stentoft J; Hokland P; Ostergaard M; Hasle H; Nyvold CG
Leuk Res; 2006 Apr; 30(4):389-95. PubMed ID: 16243396
[TBL] [Abstract][Full Text] [Related]
37. Auto-SCT for AML in second remission: CALGB study 9620.
Linker CA; Owzar K; Powell B; Hurd D; Damon LE; Archer LE; Larson RA;
Bone Marrow Transplant; 2009 Sep; 44(6):353-9. PubMed ID: 19289999
[TBL] [Abstract][Full Text] [Related]
38. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
[TBL] [Abstract][Full Text] [Related]
39. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
[TBL] [Abstract][Full Text] [Related]
40. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
